Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Iveric Bio
Public Company Edition: MAIA launches a $10m initial public offering, the first in the US since May, but NewAmsterdam opts for the SPAC route to the stock market. Also, Legend raises $350m in a follow-on offering, Iveric obtains access to $250m in debt and Otonomy cuts costs after a Phase II failure.
Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.
Two veterans of the ophthalmology field are reuniting to launch a portfolio-based biotech company EyeBio.
Public Company Edition: Xilio, Ventyx, MiNK and Context went public in the US and later traded at or above their initial public offering prices. Also, Sarepta raised $500m and Relay grossed $350m in new offerings, while Oncopeptides, Esperion, Zymergen and Ardelyx reorganized and cut jobs.
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Inception 4, Inc.
- Ophthotech Corporation (OPHT)